Julie Johnson sold Moderna Inc (NASDAQ: MRNA)
Julie Johnson (D-TX), a U.S. Representative, has disclosed 1 trade in Moderna Inc (MRNA) since 2025, a single sale, worth an estimated $8K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).
The trade highlighted here is a sale: Julie Johnson sold $1,001 - $15,000 of Moderna Inc (NASDAQ: MRNA) on January 15, 2025. Since that trade, MRNA is up +56.72% against the S&P 500 up +24.84%, an outperformance of +31.87%.
Data updated
Julie Johnson's MRNA trades vs the price
MRNA is up +56.72% since Julie Johnson sold on January 15, 2025, versus +24.84% for the S&P 500.
Performance since this trade
All Julie Johnson MRNA trades
Julie Johnson & MRNA trading FAQ
Is it legal for Julie Johnson to trade Moderna Inc (MRNA) stock?
Yes. Members of Congress are allowed to trade individual stocks, including Moderna Inc (MRNA), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; this page does not imply the trade was improper.
When did Julie Johnson sell MRNA?
Julie Johnson disclosed a sale of $1,001 - $15,000 of Moderna Inc (MRNA) on January 15, 2025, according to public STOCK Act filings.
How has MRNA performed since Julie Johnson's trade?
Since Julie Johnson sold MRNA on January 15, 2025, the stock is up +56.72%, versus +24.84% for the S&P 500 over the same period, an outperformance of +31.87%.
How soon must members of Congress disclose a trade?
Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.
Where can I see all congressional MRNA trades?
Quantellect tracks every disclosed congressional trade in Moderna Inc (MRNA) on the Moderna Inc congressional trading page, which aggregates filings across all members of Congress.
Julie Johnson's MRNA tradesAll congressional filings for Moderna IncJulie Johnson's full profile
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.